Preclinical Validation of Human Apyrase in Stroke Models

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$187,435.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43NS060175-01
Agency Tracking Number:
NS060175
Solicitation Year:
2007
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC., 893 NORTH WARSON ROAD, SAINT LOUIS, MO, 63141
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
192266141
Principal Investigator:
RIDONG CHEN
(314) 608-6932
RCHEN@NIDUSCENTER.COM
Business Contact:
RIDONG CHEN
(314) 812-8054
rchen@niduscenter.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered a human apyrase, APT102, which exhibits significantly higher enzymatic activity and platelet inhibition than the wild-type apyrases. Importantly, APT102 conferred cerebroprotection against experimental stroke without inducing intracerebral hemorrhage. With the Phase I grant support, we will develop a process for high-yield purification of APT102. We will then utilize clinically relevant embolic model to validate whether APT102 provides significant neuroprotective effect without increased bleeding risk. Human apyrase represents a highly promising therapy for acute ischemic stroke. We will utilize a clinically relevant embolic model to validate whether the protein provides significant neuroprotective effect without increased bleeding risk.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government